Latest news
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 14:00:27 GMTAquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTSilence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:30:00 GMTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMTCullinan Therapeutics Announces Positive FDA Feedback for CLN-049 and Plans Potentially Registrational Phase 2 Study in Relapsed/Refractory AML - MoomooMoomoo · Tue, 28 Jul 2026 11:13:00 GMTCullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 11:00:00 GMTCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML - SahmSahm · Tue, 28 Jul 2026 07:00:00 GMTFor AML patients with limited options, Cullinan plans a new study - Stock TitanStock Titan · Tue, 28 Jul 2026 07:00:00 GMT